Company Overview of The Multiple Myeloma Research Foundation, Inc
Key Executives for The Multiple Myeloma Research Foundation, Inc
Chief Executive Officer, President and Chief Operating Officer
Founder and Executive Chairman
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.
The Multiple Myeloma Research Foundation, Inc Key Developments
The Multiple Myeloma Research Foundation Appoints Wynton Marsalis to Honorary Board of Directors
Mar 10 15
The Multiple Myeloma Research Foundation (MMRF) announced that Managing and Artistic Director of Jazz at Lincoln Center, Wynton Marsalis has joined the MMRF Honorary Board.
The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM
Feb 22 15
The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Daniel Auclair, Vice President, Translational Research.
Inflection Biosciences Ltd Announces Collaboration with The Multiple Myeloma Research Foundation
Feb 9 15
Inflection Biosciences Ltd. announced a collaboration with the Multiple Myeloma Research Foundation on pre-clinical testing of its innovative dual mechanism PIM/PI3K inhibitor IBL-202. PIM and PI3K are two key regulators in signalling pathways that have proved essential for the proliferation and survival of myeloma cells. The MMRF investigators will test the effectiveness of IBL-202 alone and in combination with other therapeutics in pre-clinical models of multiple myeloma. These models are recognised to be predictive of clinical efficacy in cancer patients with multiple myeloma. IBL-202 is a dual mechanism kinase inhibitor that selectively inhibits PIM and PI3K without affecting the activity of other kinases. MMRF support will greatly assist in further evaluating the potential of IBL-202 for patients with multiple myeloma, one of the many indications hope to consider. The MMRF is working with Inflection Biosciences through its Translational Network of Excellence program, which supports critical research at leading academic medical centers focused on promising investigational therapies for multiple myeloma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries